Sales of Merck’s longtime oncology blockbuster Keytruda will erode more starkly in about 2033 rather than 2029, predicts ...

Synthekine Inc., an engineered cytokine therapeutics company, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the ...

The patent cliff for Keytruda is fast approaching in the U.S. Now, as Merck & Co. increasingly looks to life after its ...

The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss.

But now, 13 years after the FDA initially blessed it for skin cancer, the U.S. regulator has approved Keytruda as a second- or third-line treatment for patients with a certain type of ovarian cancer.

The approvals stem from the Phase III KEYNOTE-B96 trial data, which was presented at the 2025 ESMO Congress.

Adagene (NASDAQ:ADAG) highlighted updated details around its lead immuno-oncology program, ADG126, during an Oppenheimer ...

By Padmanabhan Ananthan Feb 23 (Reuters) - Merck said on Monday it would create a separate division for its cancer business, anchored by its top-selling drug Keytruda, as the U.S. drugmaker braces for ...

Feb 23 (Reuters) - Drugmaker Merck is separating its human-health business into two divisions to offset pressures related to ...

The new structure will help Merck as it slides toward a loss of exclusivity for Keytruda, pharma’s best-selling drug.

Merck & Co., Inc. (NYSE:MRK) is included among the 14 Best Affordable Dividend Stocks to Buy According to Analysts. On February 25, RBC Capital initiated coverage of Merck & Co., Inc. (NYSE:MRK) with ...

The company might bend, but it won't break.